We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+20.44%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$504M
AUM Growth
+$16.8M
Cap. Flow
-$13M
Cap. Flow %
-2.59%
Top 10 Hldgs %
59.9%
Holding
52
New
17
Increased
6
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$26.4M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$23.2M
3
PTCT icon
PTC Therapeutics
PTCT
+$17.8M
4
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$13M
5
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$8.5M

Top Sells

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$27.7M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$20.4M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$17.6M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$15.9M
5
TRVN
Trevena, Inc.
TRVN
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 72.8%
2 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
26
DELISTED
Blueprint Medicines
BPMC
$4.88M 0.97%
+122,129
New +$4.37M
MYOV
27
DELISTED
Myovant Sciences Ltd.
MYOV
$4.79M 0.95%
407,559
+57,559
+16% +$660K
CNXR
28
DELISTED
Connecture, Inc.
CNXR
$4.42M 0.88%
4,127,232
– –
JAZZ icon
29
Jazz Pharmaceuticals
JAZZ
$15.9B
$3.63M 0.72%
+25,000
New +$3.26M
AIMT
30
DELISTED
Aimmune Therapeutics
AIMT
$2.66M 0.53%
+122,455
New +$2.51M
RDUS
31
PUT
DELISTED
Radius Health, Inc.
RDUS
$1.93M 0.38%
+50,000
New +$2.1M
ACOR
32
CALL
DELISTED
Acorda Therapeutics
ACOR
$1.68M 0.33%
+667
New +$1.92M
CASC
33
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.56M 0.31%
+377,900
New +$1.59M
TRVN
34
DELISTED
Trevena, Inc.
TRVN
$1.24M 0.25%
541
-4,260
-89% -$14.5M
ARDM
35
DELISTED
Aradigm Corp Common Stock
ARDM
$988K 0.2%
637,279
-154,591
-20% -$287K
ALNY icon
36
Alnylam Pharmaceuticals
ALNY
$27.5B
$590K 0.12%
11,517
-40,418
-78% -$1.87M
STRM
37
DELISTED
Streamline Health Solutions
STRM
$155K 0.03%
10,107
– –
ACAD icon
38
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-270,000
Closed -$7.79M
ATXS
39
DELISTED
Astria Therapeutics
ATXS
– –
-9,276
Closed -$2.01M
BCRX icon
40
CALL
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-500,000
Closed -$3.17M
BCRX icon
41
PUT
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-725,000
Closed -$4.59M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$366M
– –
-828,253
Closed -$27.7M
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$340M
– –
-375,000
Closed -$9.15M
TENX icon
44
Tenax Therapeutics
TENX
$363M
– –
-35
Closed -$2.16M
ALIM
45
DELISTED
Alimera Sciences
ALIM
– –
-152,912
Closed -$2.48M
MRTX
46
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-870,261
Closed -$4.13M
ISEE
47
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-7,100
Closed -$34K
DERM
48
DELISTED
Dermira, Inc.
DERM
– –
-114,080
Closed -$3.46M
MDCO
49
PUT
DELISTED
Medicines Co
MDCO
– –
-750,000
Closed -$25.5M
OCRX
50
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-1,963,777
Closed -$4.12M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2017 Portfolio in Review

As of Q1 2017, Great Point Partners held 52 positions worth $504M, up 3.4% from $487M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners's Q1 2017 filing shows 17 new, 6 increased, 8 reduced and 15 closed positions. Its largest new stake was Concert Pharmaceuticals, Inc.: 2,200,000 shares worth $37.5M. The largest sale was Enanta Pharmaceuticals, an estimated $27.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 81% a quarter earlier, followed by Technology.

  • Great Point Partners's largest Q1 2017 buy was Concert Pharmaceuticals, Inc.: 2,200,000 shares worth $37.5M.
  • Great Point Partners added most to Synergy Pharmaceuticals, Inc Common Stock in Q1 2017, an estimated $13M increase.
  • Great Point Partners's biggest Q1 2017 reduction was Global Blood Therapeutics, Inc., cutting an estimated $17.6M.
  • Great Point Partners fully exited Enanta Pharmaceuticals in Q1 2017, selling an estimated $27.7M.
  • Great Point Partners's ten largest holdings make up 60% of its $504M portfolio in Q1 2017.
  • Great Point Partners opened 17 new positions and closed 15 in Q1 2017.
  • Great Point Partners's portfolio value rose 3.4% quarter-over-quarter to $504M.

Based on Great Point Partners's 13F filing for Q1 2017, filed 15 May 2017.